Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dihydromorphine is a semisynthetic opioid analgesic of the morphinane alkaloid class, structurally related to morphine. It is used for moderate to severe pain relief and has a slightly higher potency than morphine (about 1.2 times). Dihydromorphine acts primarily as an agonist at the μ-opioid receptor, with additional activity at δ-opioid and κ-opioid receptors, leading to its analgesic effects. It is also an active metabolite of dihydrocodeine via CYP2D6 metabolism. Dihydromorphine has a rapid onset and longer duration of action compared to morphine (4–7 hours). In the United States, it is classified as a Schedule I controlled substance due to its high abuse potential and lack of accepted medical use[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dihydromorphine.